Jade Biosciences, Inc. Stockholders Equity

Quick Answer

Jade Biosciences, Inc. reported Stockholders Equity of $332.52 million for fiscal year 2025.

Jade Biosciences, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $332.52M +810.5%
2024 -$46.80M -4680000.0%
2024 $1.0K -100.0%
2023 $109.46M -13.6%
2022 $126.74M -26.5%
2021 $172.42M +1392.1%
2020 -$13.34M -266.3%
2019 -$3.64M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $179.35M +1163.5% -11.0%
June 30, 2025 $201.56M +34320.0% +341.4%
March 31, 2025 -$83.51M -191.9% -78.4%
December 31, 2024 -$46.80M -142.8% -177.5%
September 30, 2024 -$16.86M -113.4% -2763.0%
June 30, 2024 -$589.0K -100.4% -100.6%
March 31, 2024 $90.90M -19.6% -16.9%
December 31, 2023 $109.46M -13.6% -12.9%
  • Jade Biosciences, Inc. showed an increase of +810.5% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2019–2025 period, Jade Biosciences, Inc.’s stockholders equity has grown by 9227.6% (from -$3.64 million to $332.52 million).
  • The most recent figure is from Jade Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment